Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 66 Show results per page	View Search Criteria \| Help With Results


1.		Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				TaCyDexVMP7 NCT00652041


2.		Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 70				Other				UARK 2003-26 NCT00090493


3.		Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 and over				Other				01-002-0601 NCT00205751


4.		Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				12 to 80				Other				A-39/29.1.2007 ICMR No-5/8/7/26/99-ECD-I, NCT00522405


5.		Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				RFA005 NCT00728078

Last Modified: 9/19/2008 First Published: 11/1/2002


6.		Phase III Randomized Study of Thalidomide and Prednisone as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 and over				NCI, Other				CAN-NCIC-MY10 NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10

Last Modified: 6/6/2008 First Published: 9/16/2005


7.		Phase III Randomized Study of Induction Therapy Comprising Two Different Doses of High-Dose Melphalan and Amifostine Followed by Single or Double Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Maintenance Therapy Comprising Clarithromycin, Thalidomide, and Dexamethasone in Patients With Stage II or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				NCI, Pharmaceutical / Industry				FHCRC-2004.00 MEDIMMUNE-FHCRC-2004.00, NCT00217438


8.		Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				20 and over				Pharmaceutical / Industry				T2202 NCT00225290


9.		MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EudraCT: 2005-001628-35 EBMT-CLWP: 42206611, NCT00256776

Last Modified: 8/4/2008 First Published: 1/28/2007


10.		Phase III Randomized Study of Zoledronate With or Without Thalidomide in Patients With Early Stage Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MAYO-MC0289 MAYO-IRB-421-03, NCT00432458

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute